December 1, 2024 - 16:33

As the new administration approaches, industry experts are contemplating significant shifts in the cryptocurrency landscape. Mark Palmer, a Managing Director and Senior Research Analyst, recently shared his insights on potential regulatory changes that could reshape the sector.
Palmer highlighted the pressing need for a more structured approach to cryptocurrency regulation, contrasting it with the current strategy employed by the SEC under Gary Gensler. He criticized what he termed "regulation by enforcement," which has created uncertainty for institutional investors. This lack of a clear regulatory framework has deterred many from engaging with the burgeoning asset class, as they fear sudden interventions from federal regulators could jeopardize their projects.
The hope is that the incoming administration will usher in a more conducive environment for crypto, fostering institutional adoption and innovation. The anticipation surrounding these changes reflects a broader desire within the industry for clarity and stability, which could ultimately lead to a more robust and secure cryptocurrency market.
May 9, 2026 - 22:04
Compass Diversified Q1 Earnings Call HighlightsCompass Diversified, the publicly traded holding company known as CODI, reported its first-quarter 2026 earnings this week, with management framing the period as one of disciplined execution. Chief...
May 9, 2026 - 00:34
Urbana Corporation Has Filed 2026 First Quarter Interim Financial StatementsTORONTO - Urbana Corporation has submitted its unaudited interim financial statements and management discussion for the first quarter of 2026. The filing covers the three-month period ending March...
May 8, 2026 - 11:59
Australia regulator calls for urgent cybersecurity action to counter MythosAustralia`s corporate watchdog has called on the country`s financial industry to take urgent steps to address cybersecurity risks posed by advanced artificial intelligence systems, including a...
May 7, 2026 - 20:22
IN8bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsIN8bio, a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, announced its financial results for the first quarter of 2026 along with key business updates. The...